CMS Initial Ruling Places Genetic Tests in Lab Fee Schedule; Favors Gapfill to Fix Payment | GenomeWeb

This article has been updated to clarify CMS's initial determination on the reimbursement process for AMA's new molecular pathology test codes.

NEW YORK (GenomeWeb News) – The Centers for Medicare & Medicaid Services last week issued a preliminary decision to place new Current Procedural Terminology codes for molecular diagnostics that it determines fall under its clinical laboratory fee schedule to be reimbursed via the so-called "gapfill" process.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.